FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non–Small-Cell Lung Cancer

Abstract

A ctivating mutations in the epidermal growth factor receptor (EGFR) are found in approx-imately 10% to 15% of non–small-cell lung cancer (NSCLC) patients in the United States and up to 35% of those in East Asia. 1,2 Patients with this mutation are more likely to be female, Asian, and nonsmokers than the general lung cancer population. For patients with these mutations, treatment with EGFR tyrosine kinase inhibitors (TKIs) erlotinib, afa-tinib, or gefitinib is associated with higher response rates and improved progression-free sur-vival (PFS) compared with standard platinum-based doublet chemotherapy. 3,4